Analyst Ratings For Atara Biotherapeutics (NASDAQ:ATRA)
Today, Atara Biotherapeutics (NASDAQ:ATRA) stock was downgraded by JMP Securities from Market Outperform to Market Perform.
Some recent analyst ratings include
- 2/28/2018-JMP Securities was Downgraded by analysts at JMP Securities from a “Market Outperform ” rating to a ” Market Perform” rating.
- 2/15/2018-Citigroup was Downgraded by analysts at Citigroup from a “Neutral ” rating to a ” Sell” rating.
- 1/26/2018-Cowen initiated coverage with a Outperform rating.
- 1/19/2018-Canaccord Genuity Reiterated Rating of Buy .
- 10/6/2017-Goldman Sachs Group Reiterated Rating of Neutral .
- 10/5/2017-Jefferies Group Reiterated Rating of Buy.
- 6/26/2017-William Blair Reiterated Rating of Outperform.
Recent Insider Trading Activity For Atara Biotherapeutics (NASDAQ:ATRA)
Atara Biotherapeutics (NASDAQ:ATRA) has insider ownership of 16.20% and institutional ownership of 74.29%.
- On 2/22/2018 Isaac E Ciechanover, CEO, sold 17,800 with an average share price of $44.65 per share and the total transaction amounting to $794,770.00.
- On 2/20/2018 Isaac E Ciechanover, CEO, sold 8,700 with an average share price of $45.28 per share and the total transaction amounting to $393,936.00.
- On 2/16/2018 Carol Giltner Gallagher, Director, sold 1,183 with an average share price of $46.50 per share and the total transaction amounting to $55,009.50.
- On 2/16/2018 Isaac E Ciechanover, CEO, sold 20,000 with an average share price of $46.92 per share and the total transaction amounting to $938,400.00.
- On 2/16/2018 John Mcgrath, CFO, sold 13,000 with an average share price of $47.07 per share and the total transaction amounting to $611,910.00.
- On 2/14/2018 Isaac E Ciechanover, CEO, sold 20,000 with an average share price of $46.80 per share and the total transaction amounting to $936,000.00.
- On 2/9/2018 Heather D Turner, EVP, sold 12,214 with an average share price of $38.01 per share and the total transaction amounting to $464,254.14.
Recent Trading Activity for Atara Biotherapeutics (NASDAQ:ATRA)
Shares of Atara Biotherapeutics closed the previous trading session at 39.15 down -3.40 7.99% with 39.29999923706055 shares trading hands.